HCV positive donor kidney pulsatile perfusion preservation

Pulsatile perfusion of HCV-positive donor kidneys is a preservation strategy intended to reduce the viral burden carried by an organ before transplantation. Its decisive significance lies in addressing the central hazard of using kidneys from HCV-positive donors: transplantation can transmit HCV, yet discarding these kidneys worsens the shortage of organs available to patients with end-stage renal disease.

Clinical Context

HCV-positive kidneys belong to the broader category of nonstandard-risk organs because HCV can be transmitted through transplantation. Their use remains controversial, and practices vary widely between transplant centers; some centers do not accept such kidneys, while some countries have technical or legal provisions that prohibit their transplantation. The shortage is substantial: demand for donated kidneys greatly exceeds supply, and many patients deteriorate or die while waiting. For HCV-positive recipients who cannot undergo, decline, fail, or discontinue antiviral treatment, transplantation may nevertheless offer a more favorable course than remaining on dialysis, while also shortening the waiting period.

This context gives preservation technology a practical, rather than merely technical, role. HCV-positive kidneys may be discarded because an appropriate recipient is not available, and donated HCV-positive kidneys have been reported to be 2.60 times more likely to be discarded than HCV-negative kidneys. A method that could lower the organ’s viral burden therefore enters a larger system of allocation, risk assessment, and unequal access to transplantation: it may make an otherwise rejected kidney more usable without pretending that the infection risk has disappeared.

Mechanism and Evidence

Pulsatile pump perfusion was reported to reduce the HCV viral load in HCV-positive kidneys. The proposed benefit is a decrease in the amount of virus present in the procured organ and, consequently, a potential reduction in HCV transmission after transplantation. The technique was examined specifically in studies of HCV transmission through kidney transplantation and in work describing depletion of HCV from procured kidneys during pulsatile perfusion preservation.

The evidence is encouraging but limited. The studies documenting viral-load reduction have not been reproduced in more recent investigations, so the effect cannot be treated as conclusively established across all preservation settings. Even so, the available findings provide a biologically plausible reason to prefer pulsatile perfusion when an HCV-positive kidney is intended for transplantation and the equipment and logistics are available.

Recommendation and Limits

The recommended position is conditional: pulsatile perfusion, rather than cold storage alone, should be used for HCV-positive kidneys if it is available. This is not a claim that perfusion sterilizes the kidney, prevents every transmission event, or removes the need for recipient counseling and post-transplant monitoring. It is a risk-reduction measure within a decision that already weighs infection, waiting time, dialysis-related mortality, graft outcomes, and the recipient’s treatment options.

The limits of the intervention are especially important because HCV-positive recipients are not necessarily protected from acquiring an additional infection. A recipient with preexisting HCV can experience superinfection with a different genotype, or even with the same genotype, and a donor-recipient genotype mismatch has been associated with a report of severe liver disease. Pulsatile perfusion may reduce the viral burden in the kidney, but it does not substitute for virologic assessment, consideration of donor-recipient genotype, or careful management of HCV before and after transplantation.

Place in Transplant Decision-Making

The technique is best understood as one component of an evidence-based strategy for expanding access to transplantation. HCV infection is a systemic disease that can affect the liver, kidneys, and other organ systems, and HCV-positive dialysis patients face increased mortality. A meta-analysis of 11,589 dialysis patients found an adjusted relative risk of 1.34 for all-cause mortality associated with anti-HCV antibody positivity, while liver-related mortality was markedly higher in anti-HCV-positive patients. These risks help explain why prolonging dialysis solely to avoid an HCV-positive kidney may itself carry serious consequences.

At the same time, transplantation does not erase the disadvantages associated with HCV. HCV-positive recipients have worse long-term graft and patient survival than HCV-negative recipients, and HCV has been associated with post-transplant diabetes, post-transplant glomerulonephritis, proteinuria, and chronic allograft nephropathy. Antiviral therapy before transplantation may reduce some complications, but it can be prolonged, costly, poorly tolerated, and unavailable or unsuccessful for some patients. In that setting, pulsatile perfusion offers a way to reduce one component of risk while preserving the possibility of transplantation for recipients who might otherwise remain on dialysis.

Significance

Pulsatile perfusion makes the HCV-positive kidney neither risk-free nor automatically unacceptable. Its importance lies in converting preservation from passive storage into an intervention that may alter the infectious profile of the organ. The recommendation to use it when possible reflects a balance between incomplete evidence and an urgent clinical reality: kidneys are scarce, HCV-positive organs are frequently discarded, and some HCV-positive patients may gain more from receiving such a kidney than from waiting indefinitely while exposed to the hazards of long-term dialysis. In that balance, viral-load reduction is presented as a cautious but potentially valuable means of making transplantation safer and organ use more equitable.